Risk of cancer in patients with osteoporosis treated with osteoporotic therapy (alendronic acid, ibandronic acid,zolendronic acid,raloxifen,teriparatide,denosumab)

Trial Profile

Risk of cancer in patients with osteoporosis treated with osteoporotic therapy (alendronic acid, ibandronic acid,zolendronic acid,raloxifen,teriparatide,denosumab)

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Alendronic acid (Primary) ; Denosumab (Primary) ; Ibandronic acid (Primary) ; Raloxifene (Primary) ; Teriparatide (Primary) ; Zoledronic acid (Primary)
  • Indications Osteoporosis
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top